ChemicalBook >
Produktkatalog >
Analytische Chemie >
Standard >
Pharmazeutische Referenzstandards und Verunreinigungsreferenzstandards >(R)-10-(2,4,5-trifluorobenzyl)-3-(trifluoromethyl)-6,7,10,11-tetrahydro-[1,2,4]triazolo[3,4-c][1,4,7]triazecine-8,12(5H,9H)-dione
(R)-10-(2,4,5-trifluorobenzyl)-3-(trifluoromethyl)-6,7,10,11-tetrahydro-[1,2,4]triazolo[3,4-c][1,4,7]triazecine-8,12(5H,9H)-dione
|
|
|
- CAS-Nr.
- 2088771-61-1
- Englisch Name:
- (R)-10-(2,4,5-trifluorobenzyl)-3-(trifluoromethyl)-6,7,10,11-tetrahydro-[1,2,4]triazolo[3,4-c][1,4,7]triazecine-8,12(5H,9H)-dione
- Synonyma:
- Impurity FP-B;Sitagliptin-17;Sitagliptin Impurity 20;Sitagliptin FP Impurity B;Sitagliptin Impurity FP-B;Sitagliptin Triazecine Impurity;(R)-10-(2,4,5-trifluorobenzyl)-3-(trifluoromethyl);Sitagliptin FP Impurity B/ Sitagliptin Triazecine Analog;(R)-Sitagliptin Tablets EP Impurity FP-B ((R)-Sitagliptin Triazecine Analog);(R)-10-(2,4,5-trifluorobenzyl)-3-(trifluoromethyl)-6,7,10,11-tetrahydro-[1,2,4]triazolo[3,4-c][1,4,7]triazecine-8,12(5H,9H)-dione
- CBNumber:
- CB23371367
- Summenformel:
- C16H13F6N5O2
- Molgewicht:
- 421.3
- MOL-Datei:
- 2088771-61-1.mol
|
(R)-10-(2,4,5-trifluorobenzyl)-3-(trifluoromethyl)-6,7,10,11-tetrahydro-[1,2,4]triazolo[3,4-c][1,4,7]triazecine-8,12(5H,9H)-dione Eigenschaften
- Schmelzpunkt:
- >189°C (dec.)
- Dichte
- 1.67±0.1 g/cm3(Predicted)
- storage temp.
- -20°C Freezer, Under inert atmosphere
- Löslichkeit
- DMSO (Slightly), Methanol (Slightly)
- pka
- 12.02±0.40(Predicted)
- Aggregatzustand
- Solid
- Farbe
- White to Off-White
- InChI
- InChI=1S/C16H13F6N5O2/c17-9-6-11(19)10(18)4-7(9)3-8-5-12(28)23-1-2-27-13(14(29)24-8)25-26-15(27)16(20,21)22/h4,6,8H,1-3,5H2,(H,23,28)(H,24,29)/t8-/m1/s1
- InChIKey
- CJUCSNDPMOGZTM-MRVPVSSYSA-N
- SMILES
- N1[C@H](CC2=CC(F)=C(F)C=C2F)CC(=O)NCCN2C(C(F)(F)F)=NN=C2C1=O
Sicherheit
(R)-10-(2,4,5-trifluorobenzyl)-3-(trifluoromethyl)-6,7,10,11-tetrahydro-[1,2,4]triazolo[3,4-c][1,4,7]triazecine-8,12(5H,9H)-dione Chemische Eigenschaften,Einsatz,Produktion Methoden
Verwenden
(10R)-Sitagliptin Triazecine Analog is related to the family of Sitagliptin compounds which has recently been approved for the therapy of type II diabetes.
(R)-10-(2,4,5-trifluorobenzyl)-3-(trifluoromethyl)-6,7,10,11-tetrahydro-[1,2,4]triazolo[3,4-c][1,4,7]triazecine-8,12(5H,9H)-dione Upstream-Materialien And Downstream Produkte
Upstream-Materialien
Downstream Produkte
(R)-10-(2,4,5-trifluorobenzyl)-3-(trifluoromethyl)-6,7,10,11-tetrahydro-[1,2,4]triazolo[3,4-c][1,4,7]triazecine-8,12(5H,9H)-dione Anbieter Lieferant Produzent Hersteller Vertrieb Händler.
Global( 59)Lieferanten
2088771-61-1()Verwandte Suche:
- Impurity FP-B
- Sitagliptin Impurity 20
- Sitagliptin-17
- Sitagliptin FP Impurity B
- (R)-10-(2,4,5-trifluorobenzyl)-3-(trifluoromethyl)
- Sitagliptin impurity 6/Sitagliptin FP Impurity B/Sitagliptin Triazecine Analog/10-(2,4,5-Trifluorobenzyl)-3-(trifluoromethyl)-6,7,10,11-tetrahydro [1,2,4] triazolo [3,4-c][1,4,7]triazecine-8,12(5H,9H)-dione
- 1,2,4-Triazolo[3,4-c][1,4,7]triazecine-8,12(5H,9H)-dione, 6,7,10,11-tetrahydro-3-(trifluoromethyl)-10-[(2,4,5-trifluorophenyl)methyl]-, (10R)-
- (10R)?- 6,?7,?10,?11-?Tetrahydro-?3-?(trifluoromethyl)?-?10-?[(2,?4,?5-?trifluorophenyl)?methyl]?-1,?2,?4-?triazolo[3,?4-?c]?[1,?4,?7]?triazecine-?8,?12(5H,?9H)?-?dione
- Sitagliptin FP Impurity B/ Sitagliptin Triazecine Analog
- (R)-10-(2,4,5-trifluorobenzyl)-3-(trifluoromethyl)-6,7,10,11-tetrahydro-[1,2,4]triazolo[3,4-c][1,4,7]triazecine-8,12(5H,9H)-dione
- Sitagliptin Impurity FP-B
- (R)-10-(2,4,5-trifluorobenzyl)-3-(trifluoromethyl)-6,7,10,11-tetrahydro-[1,2,4]triazolo[3,4-c][1,4,7]triazecine-8,12(5H,9H)-dione? (Sitagliptin Impurity）
- Sitagliptin Triazecine Impurity
- (R)-Sitagliptin Tablets EP Impurity FP-B ((R)-Sitagliptin Triazecine Analog)
- 2088771-61-1
- C16H13F6N5O2
